KR20240119299A - 피라졸로[3,4-d]피리미딘 화합물의 고체 형태 - Google Patents

피라졸로[3,4-d]피리미딘 화합물의 고체 형태 Download PDF

Info

Publication number
KR20240119299A
KR20240119299A KR1020247023041A KR20247023041A KR20240119299A KR 20240119299 A KR20240119299 A KR 20240119299A KR 1020247023041 A KR1020247023041 A KR 1020247023041A KR 20247023041 A KR20247023041 A KR 20247023041A KR 20240119299 A KR20240119299 A KR 20240119299A
Authority
KR
South Korea
Prior art keywords
solid form
approximately
certain embodiments
solid
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247023041A
Other languages
English (en)
Korean (ko)
Inventor
캐롤라인 이베트 프로울스-라프랑스
에리카 볼크코바
주니어 존 씨 아메디오
Original Assignee
화이자 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 화이자 인크. filed Critical 화이자 인크.
Publication of KR20240119299A publication Critical patent/KR20240119299A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020247023041A 2021-12-16 2022-12-16 피라졸로[3,4-d]피리미딘 화합물의 고체 형태 Pending KR20240119299A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163290136P 2021-12-16 2021-12-16
US63/290,136 2021-12-16
PCT/US2022/081795 WO2023114995A1 (en) 2021-12-16 2022-12-16 Solid forms of pyrazolo[3,4-d]pyrimidine compounds

Publications (1)

Publication Number Publication Date
KR20240119299A true KR20240119299A (ko) 2024-08-06

Family

ID=85172741

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247023041A Pending KR20240119299A (ko) 2021-12-16 2022-12-16 피라졸로[3,4-d]피리미딘 화합물의 고체 형태

Country Status (11)

Country Link
US (2) US12012412B2 (cg-RX-API-DMAC10.html)
EP (1) EP4448529A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024546844A (cg-RX-API-DMAC10.html)
KR (1) KR20240119299A (cg-RX-API-DMAC10.html)
CN (1) CN118401525A (cg-RX-API-DMAC10.html)
AU (2) AU2022416644B2 (cg-RX-API-DMAC10.html)
CA (1) CA3242577A1 (cg-RX-API-DMAC10.html)
IL (1) IL313314A (cg-RX-API-DMAC10.html)
MX (1) MX2024007517A (cg-RX-API-DMAC10.html)
TW (1) TW202333676A (cg-RX-API-DMAC10.html)
WO (1) WO2023114995A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024546844A (ja) 2021-12-16 2024-12-26 ファイザー・インク ピラゾロ[3,4-d]ピリミジン化合物の固体形態
WO2025043067A2 (en) * 2023-08-22 2025-02-27 Cardurion Pharmaceuticals, Inc. Pyrazolo[3,4-d]pyrimidinone compounds for the treatment of chronic heart failure

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
PT2152712E (pt) 2007-05-11 2012-02-29 Pfizer Compostos amino-heterocíclicos
CN109893653A (zh) * 2017-12-11 2019-06-18 王慧敏 Pde9抑制剂的新用途
JP2024546844A (ja) * 2021-12-16 2024-12-26 ファイザー・インク ピラゾロ[3,4-d]ピリミジン化合物の固体形態

Also Published As

Publication number Publication date
CA3242577A1 (en) 2023-06-22
US12012412B2 (en) 2024-06-18
US20240300961A1 (en) 2024-09-12
TW202333676A (zh) 2023-09-01
JP2024546844A (ja) 2024-12-26
IL313314A (en) 2024-08-01
CN118401525A (zh) 2024-07-26
AU2025275149A1 (en) 2026-01-08
WO2023114995A1 (en) 2023-06-22
EP4448529A1 (en) 2024-10-23
AU2022416644B2 (en) 2025-09-11
AU2022416644A1 (en) 2024-07-04
MX2024007517A (es) 2024-08-19
NZ812114A (en) 2025-08-29
US20230192707A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
JP2021530456A (ja) 2−(3,5−ジクロロ−4−((5−イソプロピル−6−オキソ−1,6−ジヒドロピリダジン−3−イル)オキシ)フェニル)−3,5−ジオキソ−2,3,4,5−テトラヒドロ−1,2,4−トリアジン−6−カルボニトリルの固体形態
US20240300961A1 (en) Solid forms of pyrazolo[3,4-d]pyrimidine compounds
EP4010322B1 (en) Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof
AU2022283638A1 (en) Co-crystal forms of a novobiocin analog and proline
US20230049311A1 (en) Methods of treating desmoid tumors with (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide
KR20250144991A (ko) Apj 수용체 활성을 갖는 화합물의 염 및 고체 형태
WO2025137366A2 (en) Solid-state forms of stat3 inhibitors and methods of use thereof
US20220251091A1 (en) Amorphous umbralisib monotosylate
US12559478B2 (en) Co-crystal forms of selinexor
US11136332B2 (en) Morphic forms of marizomib and uses thereof
US12030886B2 (en) Form of ponatinib
HK40112450A (en) Solid forms of pyrazolo[3,4-d]pyrimidine compounds
EA052651B1 (ru) ТВЕРДЫЕ ФОРМЫ ПИРАЗОЛО[3,4-d]ПИРИМИДИНОВЫХ СОЕДИНЕНИЙ
US20210246159A1 (en) Novel form of bardoxolone methyl
US11891401B2 (en) Solid forms of N-(4-fluoro-3-(6-(3-methylpyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl)-2,4-dimethyloxazole-5-carboxamide
WO2026024591A1 (en) Tryptamine prodrug solid forms
EP4326737A1 (en) Salts and crystalline forms of (3e) 3-[o-[(phosphonooxy)methyl]oxime]-pregn-4-ene-3, 20-dione and related uses
HK40074778A (en) Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof
WO2017120532A1 (en) Polymorphs of a phosphate salt of quinuclidin-4-ylmethyl 4-methyl-1h-indole-3-carboxylate and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000